TheraRadar
Data updated: May 26, 2026

MINZOYA (ethinyl estradiol)

Women's Health Approved 2024-02-15

Minzoya is a combination hormonal medication used by females of reproductive potential to prevent pregnancy. This oral contraceptive contains both progestin and estrogen to help patients manage their reproductive health. It is prescribed as a reliable method for those looking to avoid conception.

Source: FDA Label • Lupin

How MINZOYA Works

This medication primarily works by suppressing ovulation to lower the risk of pregnancy. It also causes changes in cervical mucus to inhibit sperm penetration and alters the uterine lining to reduce the likelihood of an egg implanting.

Source: FDA Label
1
Indication
--
Phase 3 Trials
2
Years on Market

Details

Status
Prescription
First Approved
2024-02-15
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: ETHINYL ESTRADIOL , LEVONORGESTREL

MINZOYA Approval History

2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2024 to 2024
Feb 2024 ORIGINAL
Update

What MINZOYA Treats

1 indications

MINZOYA is approved for 1 conditions since its original approval in 2024. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Pregnancy
Source: FDA Label

MINZOYA Boxed Warning

CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke [see Contraindications ( 4 )] . WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full Prescribing Information...

MINZOYA Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Indication competitors

3

Same indication, different mechanism — what else might this patient receive?

Unlock 1 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to MINZOYA

3 of 6

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

BALCOLTRA
ETHINYL ESTRADIOL
1 shared
AVION PHARMS
Shared indications:
Pregnancy
DOLISHALE
ETHINYL ESTRADIOL
1 shared
NOVAST LABS
Shared indications:
Pregnancy
ENILLORING
ETHINYL ESTRADIOL
1 shared
XIROMED
Shared indications:
Pregnancy
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT07340190 CDAK539A12102 2025-521000-22-00 Ph 1 not yet recruiting A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
NCT06039826 18533 J1I-MC-GZBV Ph 1 completed A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

MINZOYA FDA Label Details

Indications & Usage

MINZOYA is indicated for the treatment of Pregnancy.

⚠️ BOXED WARNING

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For th...

Track MINZOYA with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.